Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Selenium plays an essential role in the biosynthesis of selenoproteins, a unique class of proteins that incorporate selenocysteine (Sec), known as the 21st amino acid[1][4][5]. Selenocysteine incorporation into proteins occurs cotranslationally at in-frame UGA codons, which are normally stop codons, using a specialized set of factors including a Sec-specific tRNA, the SECIS (selenocysteine insertion sequence) element in mRNA, and several unique translation factors[1][2][3][4]. This process is strictly dependent on available selenium, and a hierarchy of selenoprotein expression exists under selenium-limiting conditions[4][5]. Dysregulation of selenoprotein synthesis can contribute to diseases including cancer, neurodegeneration, cardiovascular disease, and infertility[2][3]. Direct pharmacologic targeting of this pathway is not a current therapeutic strategy, but selenium supplementation is used to address dietary deficiency.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Selenium-dependent selenoprotein synthesis machinery.